We have located links that may give you full text access.
Down-regulation of microRNA-182 and microRNA-183 predicts progression of osteosarcoma.
Archives of Medical Science : AMS 2017 October
Introduction: The aim of this study was to investigate the expression levels of microRNA-182 and microRNA-183 and their association with clinicopathological features in patients with osteosarcoma.
Material and methods: Total RNA was purified from samples and noncancerous bone tissues and then quantitative real-time polymerase chain reaction was applied to evaluate the expression levels of microRNAs, and their relationship with clinicopathological features and survival in osteosarcoma patients.
Results: Our findings showed that expression of MiR-182 was clearly lower in osteosarcoma bone tissue (mean ± SD: 2.84 ±.07) compared with noncancerous bone tissues (6.23 ±1.72, p = 0.004). On the other hand, lower expression of MiR-183 was seen in osteosarcoma bone tissue (1.43 ±0.59) when compared with normal tissues (4.36 ±2.47, p = 0.036). Decreased expression of MiR-182 was clearly correlated with advanced clinical stage ( p = 0.001), metastasis or recurrence ( p = 0.024), and large tumor size ( p = 0.032). Decreased expression of MiR-183 was associated with advanced TNM stage ( p = 0.004), and metastasis or recurrence ( p = 0.002). A multivariate Cox proportional hazards model revealed that low expression of MiR-182 and MiR-183 ( p = 0.02; p = 0.016), TNM stage ( p = 0.04), and metastasis or recurrence ( p = 0.03) were significantly associated with poor survival as independent prognostic factors.
Conclusions: These findings suggest that MiR-182 and MiR-183 may be associated with progression and metastasis of osteosarcoma.
Material and methods: Total RNA was purified from samples and noncancerous bone tissues and then quantitative real-time polymerase chain reaction was applied to evaluate the expression levels of microRNAs, and their relationship with clinicopathological features and survival in osteosarcoma patients.
Results: Our findings showed that expression of MiR-182 was clearly lower in osteosarcoma bone tissue (mean ± SD: 2.84 ±.07) compared with noncancerous bone tissues (6.23 ±1.72, p = 0.004). On the other hand, lower expression of MiR-183 was seen in osteosarcoma bone tissue (1.43 ±0.59) when compared with normal tissues (4.36 ±2.47, p = 0.036). Decreased expression of MiR-182 was clearly correlated with advanced clinical stage ( p = 0.001), metastasis or recurrence ( p = 0.024), and large tumor size ( p = 0.032). Decreased expression of MiR-183 was associated with advanced TNM stage ( p = 0.004), and metastasis or recurrence ( p = 0.002). A multivariate Cox proportional hazards model revealed that low expression of MiR-182 and MiR-183 ( p = 0.02; p = 0.016), TNM stage ( p = 0.04), and metastasis or recurrence ( p = 0.03) were significantly associated with poor survival as independent prognostic factors.
Conclusions: These findings suggest that MiR-182 and MiR-183 may be associated with progression and metastasis of osteosarcoma.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app